首页> 外文期刊>Cancer Medicine >The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B-cell aggregates in the bone marrow of patients with diffuse large B-cell lymphoma
【24h】

The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B-cell aggregates in the bone marrow of patients with diffuse large B-cell lymphoma

机译:弥漫性大B细胞淋巴瘤患者骨髓中单克隆免疫球蛋白基因重排与组织学B细胞聚集体的预后意义

获取原文
           

摘要

Abstract Bone marrow involvement (BMI) is a well-known poor prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL). This study robustly investigated the significance of monoclonal immunoglobulin gene rearrangement combined with histologic B-cell aggregates in bone marrow (BM) in the detection of a poor prognostic group. Pretreatment BM samples of 394 DLBCL patients were analyzed via the immunoglobulin gene rearrangement study and the microscopic examination. Monoclonal immunoglobulin gene rearrangement was detected in 25.4% of cases. Histologic B-cell aggregates with the features of large B-cell lymphoma aggregates, small cell B-cell lymphoma aggregates, or B-cell aggregates of unknown biological potential were observed in 12% of cases (6.9%, 1.3%, and 3.8%, respectively). Histologic B-cell aggregates were more associated with monoclonality than polyclonality. Cases with both monoclonality and histologic B-cell aggregates demonstrated close association with poor prognostic factors such as a higher International Prognostic Index score and showed an inferior overall survival rate when compared to cases with only monoclonality or only histologic B-cell aggregates. From the findings, a combination of monoclonality and histologic B-cell aggregates within the bone marrow was highly associated with poor prognosis and could be used to determine high-risk DLBLC patients with greater sensitivity and specificity than conventional microscopic examination or immunoglobulin gene rearrangement study alone.
机译:摘要骨髓受累(BMI)是弥漫性大B细胞淋巴瘤(DLBCL)患者的不良预后因素。这项研究强有力地研究了单克隆免疫球蛋白基因重排与骨髓(BM)组织学B细胞聚集体结合在检测不良预后组中的意义。通过免疫球蛋白基因重排研究和显微镜检查分析了394名DLBCL患者的预处理BM样品。在25.4%的病例中检测到了单克隆免疫球蛋白基因重排。在12%的病例中观察到具有大B细胞淋巴瘤聚集体,小细胞B细胞淋巴瘤聚集体或生物学潜能未知的B细胞聚集体的组织学B细胞聚集体(6.9%,1.3%和3.8% , 分别)。组织学B细胞聚集体与单克隆性的关系比与多克隆性的关系更大。与仅具有单克隆抗体或仅具有组织学B细胞聚集体的病例相比,具有单克隆和组织学B细胞聚集体的病例均与不良预后因素(例如更高的国际预后指数评分)密切相关,并且总生存率较低。根据研究结果,骨髓内单克隆抗体和组织学B细胞聚集体的组合与不良预后高度相关,可用于确定比传统的显微镜检查或免疫球蛋白基因重排研究更高的敏感性和特异性的高危DLBLC患者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号